

DAFTAR PUSTAKA

1. Armstrong M, Asuka E, Fingeret A. Physiology, Thyroid Function. StatPearls. 13 Maret 2023. PubMed.
2. The International Agency for Research on Cancer. <https://gco.iarc.who.int/media/globocan/factsheets/cancers/32-thyroid-fact-sheet.pdf> [Internet]. 2024 [dikutip 27 April 2025]. hlm. 1. Global Cancer Observatory: Thyroid. Tersedia pada: <https://gco.iarc.who.int/media/globocan/factsheets/cancers/32-thyroid-fact-sheet.pdf>
3. Sudoyo A, Setiyohadi B, Alwi I, Simadibrata M, Setiati S. Buku Ajar Ilmu Penyakit Dalam Jilid III. Kelima. Jakarta Pusat: InternaPublishing; 2010.
4. Jameson J, Mandel S, Weetman A. Disorders of The Thyroid Gland. In: Jameson J. Harrison's Endocrinology. 4th ed. United States: McGraw Hill-Education; 2017. p. 102—106.
5. National Cancer Institute. Cancer Statistics Review, 1975-2018 - SEER Statistics [Internet]. 2021 [dikutip 27 April 2025]. Tersedia pada: https://seer.cancer.gov/archive/csr/1975_2018/
6. Zhao HH, Wilhelm SM. Exploring ethnic diversity and clinical outcome variabilities in well-differentiated thyroid cancer among the Asian population. Surgery (United States). 14 Mei 2024;177:108827.
7. Frandsen CLB, Sørensen SM, Maltesen T, Munk C, Feldt-Rasmussen U, Jensen A, dkk. Polycystic ovary syndrome and risk of differentiated thyroid cancer: A nationwide, register-based cohort study based on Danish health data. Cancer Epidemiol. 1 Januari 2025;95:102743.
8. Porter A, Wong DJ. Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions. Front Oncol. 25 Januari 2021;10.
9. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, dkk. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid . 2016;26(1).
10. Al-Osaimi MB, Abdelrazek EM, Attalla EM, Salaheldin H. Comparative evaluation of low and high radioiodine doses in differentiated thyroid carcinoma

management: A multicenter study. *J Radiat Res Appl Sci.* 1 Desember 2024;17(4):101206.

11. Aashiq M, Silverman DA, Na'ara S, Takahashi H, Amit M. Radioiodine-refractory thyroid cancer: Molecular basis of redifferentiation therapies, management, and novel therapies. *Cancers (Basel).* 17 September 2019;11(9):1382.
12. Mu ZZ, Zhang X, Lin YS. Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer. *Chonnam Med J.* 1 September 2019;55(3):127–35.
13. Liu Y, Wang J, Hu X, Pan Z, Xu T, Xu J, dkk. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. *Drug Resistance Updates.* 1 Mei 2023;68:100939.
14. Nuñez-Anita RE, Arroyo-Helguera O, Cajero-Juárez M, López-Bojorquez L, Aceves C. A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplastic effect of iodine in mammary cancer. *Prostaglandins Other Lipid Mediat.* 1 Juni 2009;89(1–2):34–42.
15. Aceves C, García-Solís P, Arroyo-Helguera O, Vega-Riveroll L, Delgado G, Anguiano B. Antineoplastic effect of iodine in mammary cancer: Participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR). *Mol Cancer.* 6 Juni 2009;8:33.
16. Zhang D, Xu X, Li J, Yang X, Sun J, Wu Y, dkk. High iodine effects on the proliferation, apoptosis, and migration of papillary thyroid carcinoma cells as a result of autophagy induced by BRAF kinase. *Biomedicine and Pharmacotherapy.* 1 Desember 2019;120:109476.
17. Aranda N, Sosa S, Delgado G, Aceves C, Anguiano B. Uptake and antitumoral effects of iodine and 6-iodolactone in differentiated and undifferentiated human prostate cancer cell lines. *Prostate.* 18 April 2012;73(1):31–41.
18. Sánchez-Díez M, Romero-Jiménez P, Alegría-Aravena N, Gavira-O'Neill CE, Vicente-García E, Quiroz-Troncoso J, dkk. Assessment of Cell Viability in Drug Therapy: IC50 and Other New Time-Independent Indices for Evaluating Chemotherapy Efficacy. *Pharmaceutics.* 1 Februari 2025;17(2).
19. Berrouet C, Dorilas N, Rejniak KA, Tuncer N. Comparison of Drug Inhibitory Effects (IC 50) in Monolayer and Spheroid Cultures. *Bull Math Biol.* 22 Desember 2022;82(6):68.

20. Gärtner R. Autoregulation of Thyroid Growth and Function by Iodine: Independent Regulation of the Thyroid Gland by Iodocompounds. *Comprehensive Handbook of Iodine: Nutritional, Biochemical, Pathological and Therapeutic Aspects*. 9 Februari 2009;25:243–7.
21. Boeynaemss JM, Hubbard WC. Transformation of arachidonic acid into an iodolactone by the rat thyroid. *Journal of Biological Chemistry*. 16 Juli 1980;255(19):9001–4.
22. Nava-Villalba M, Aceves C. 6-Iodolactone, key mediator of antitumoral properties of iodine. *Prostaglandins Other Lipid Mediat*. 10 Juli 2014;112:27–33.
23. Nava-Villalba M, Nuñez-Anita RE, Bontempo A, Aceves C. Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone. *Mol Cancer*. 17 September 2015;14(1):1–11.
24. Suchanek KM, May FJ, Robinson JA, Lee WJ, Holman NA, Monteith GR, dkk. Peroxisome proliferator-activated receptor α in the human breast cancer cell lines MCF-7 and MDA-MB-231. *Mol Carcinog*. 1 Agustus 2002;34(4):165–71.
25. Maitra A. The Endocrine System, In: Kumar V, Abbas A, Aster J. *Pathologic Basis of Disease Robbins & Cotran*. 10th ed. Canada: Elsevier; 2021. p. 1086–1091.
26. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. *Nature Reviews Endocrinology* 2011 7:10. 30 Agustus 2011;7(10):569–80.
27. Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, dkk. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. *Lancet Diabetes Endocrinol*. 1 April 2021;9(4):225–34.
28. Filetti S, Tuttle R, Leboulleux S, Alexander E. Nontoxic Diffuse Goiter, Nodular Thyroid Disorders, and Thyroid Malignancies. In: Melmed S, Auchus R, Goldfine A, Koenig R, Rosen C. *Williams Textbook of Endocrinology*. 14th ed. Canada: Elsevier; 2020. p. 445—458.
29. Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. *Curr Opin Endocrinol Diabetes Obes*. 1 Oktober 2017;24(5):332–6.
30. Perkumpulan Endokrinologi Indonesia (PERKENI). *Petunjuk Praktis Pengelolaan Nodul Tiroid*. Februari 2018.

31. Adham M, Aldino N. Diagnosis dan Tatalaksana Karsinoma Tiroid Berdiferensiasi. *ORLI*. 2018;48(2):197–209.
32. Amir N, Kasprata H, Priyahita P, Syahla T, Triani E. Clinical Diagnosis and Management of Thyroid Cancer. *Jurnal Kedokteran Unram*. 18 September 2023;12(3):240–6.
33. Agrawal A, Dhar H. Chapter 7: Radioactive Iodine Treatment in Differentiated Thyroid Cancer. *Journal of Head & Neck Physicians and Surgeons*. Januari 2024;12(Suppl 1):S36–42.
34. Nava-Villalba M, Aceves C. 6-Iodolactone, key mediator of antitumoral properties of iodine. *Prostaglandins Other Lipid Mediat*. 10 Juli 2014;112:27–33.
35. Wang Z. *Comprehensive Organic Name Reactions and Reagents*. Wiley J, editor. Wiley; 2009.
36. Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPAR α action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. *J Hepatol*. 1 Maret 2015;62(3):720–33.
37. Arroyo-Helguera O, Rojas E, Delgado G, Aceves C. Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6-iodolactone mediates apoptotic effects. *Endocr Relat Cancer*. Desember 2008;15(4):1003–11.
38. Khalef L, Lydia R, Filicia K, Moussa B. Cell viability and cytotoxicity assays: Biochemical elements and cellular compartments. *Cell Biochem Funct*. 1 April 2024;42(3).
39. Adan A, Kiraz Y, Baran Y. Cell Proliferation and Cytotoxicity Assays. *Curr Pharm Biotechnol*. 15 Agustus 2016;17(14):1213–21.
40. Vikas B, Anil S, Vikas B, Anil S. Cell-Based Assays in Cancer Research. *Cell Growth*. 27 November 2019.
41. Aslantürk ÖS. In Vitro Cytotoxicity and Cell Viability Assays: Principles, Advantages, and Disadvantages. Dalam: *Genotoxicity - A Predictable Risk to Our Actual World*. InTech; 2018.
42. Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, dkk. Cell Viability Assays. *Assay Guidance Manual*. 1 Juli 2016. PubMed.

43. Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT Assay: Utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis. *Int J Mol Sci.* 26 November 2021;22(23):1287.
44. Aykul S, Martinez-Hackert E. Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis. *Anal Biochem.* 1 September 2016;508:97–103.
45. Berrouet C, Dorilas N, Rejniak KA, Tuncer N. Comparison of Drug Inhibitory Effects (IC50) in Monolayer and Spheroid Cultures. *Bull Math Biol.* 1 Juni 2020;82(6):68.
46. Gärtner R, Rank P, Ander B. The role of iodine and δ -iodolactone in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells. *Hormones.* 2010;9(1):60–6.
47. Zhang Y, Liu Y, Sun J, Zhang W, Guo Z, Ma Q. Arachidonic acid metabolism in health and disease. *MedComm.* John Wiley and Sons Inc; 2023.
48. Thomasz L, Oglio R, Rossich L, Villamar S, Perona M, Salvarredi L, dkk. 6 Iodo- δ -lactone: A derivative of arachidonic acid with antitumor effects in HT-29 colon cancer cells. *Prostaglandins Leukot Essent Fatty Acids.* April 2013;88(4):273–80.
49. Ryan J, Curran CE, Hennessy E, Newell J, Morris JC, Kerin MJ, dkk. The sodium iodide Symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue. *PLoS One.* 2011;6(1).
50. Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: When and how do cancer cells develop chemoresistance? *Cancer Journal.* Maret 2011;17(2):89–95.
51. Srinivasan B, Lloyd MD. Dose-Response Curves and the Determination of IC50 and EC50 Values. *Journal of Medicinal Chemistry.* American Chemical Society; 2024. hlm. 17931–4.
52. Kim SI, Kim HJ, Lee HJ, Lee K, Hong D, Lim H, dkk. Application of a non-hazardous vital dye for cell counting with automated cell counters. *Anal Biochem.* 1 Januari 2016;492(2016):8–12.